Compounding HRT Solutions for Anti-Aging Longevity Protocol Patients

According to NIH MedlinePlus and the Endocrine Society Clinical Practice Guideline, low energy and reduced stamina may occur in the setting of age-related hormonal changes. These symptoms may present as diminished exercise tolerance, shortened periods of sustained activity, and prolonged recovery time following exertion, though evaluation is important because many conditions may contribute to these symptoms. Routine tasks may feel disproportionately taxing, motivational drive may wane, and concentration may decrease. Patients experiencing severe or rapidly progressing fatigue should seek evaluation from a qualified clinician, as sudden pronounced weakness may indicate an underlying endocrine or medical condition requiring urgent assessment.

According to NIH MedlinePlus and NAMS (The Menopause Society), some patients report cognitive symptoms during hormonal transitions and aging, though careful evaluation is important because many conditions may contribute. These symptoms may present as difficulty sustaining attention, slower information processing, impaired short-term memory, and reduced ability to multitask. The degree of cognitive change varies considerably among individuals. Patients experiencing significant or sudden cognitive changes should seek evaluation from a qualified clinician, as abrupt changes in cognition may indicate conditions beyond hormonal fluctuation that require medical attention.

According to NIH MedlinePlus and the Endocrine Society Clinical Practice Guideline, changes in muscle mass and strength may occur in the setting of age-related hormonal changes, though evaluation is important because many conditions may contribute. These changes may present as reduced muscle bulk, diminished force generation for daily activities, quicker fatigability, slower transitions from seated to standing, weakened grip, and reduced walking endurance. Patients experiencing significant or rapid muscle loss should seek evaluation from a qualified clinician, as such changes may indicate an underlying condition — including endocrine disorders — that requires medical assessment.

According to NIH MedlinePlus and NAMS (The Menopause Society), sleep changes may occur with aging and hormonal transitions, but evaluation is important because many conditions may contribute. These changes may present as repeated nocturnal awakenings, shortened or shallow sleep episodes, and difficulty returning to sleep, with diminished time in deep slow-wave and REM stages. Nights may feel non-restorative, contributing to daytime fatigue, impaired concentration, mood lability, and a sense of chronic under-recovery. Patients experiencing severe or persistent sleep disruption should seek evaluation from a qualified clinician, as such symptoms may indicate conditions — including sleep apnea or other disorders — that require medical assessment.

According to the FDA-approved prescribing information for Metformin, Metformin is a biguanide indicated for the improvement of glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus as an adjunct to diet and exercise. The labeling describes that Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. Per the labeling, lactic acidosis is a rare but serious metabolic complication that may occur due to Metformin accumulation; renal function should be assessed before initiating and periodically thereafter. Compounded medications are not reviewed by FDA for safety or effectiveness before dispensing. Commercially available Metformin is separately regulated, and clinical decisions belong with the prescribing clinician.

According to the FDA-approved prescribing information for naltrexone, naltrexone is an opioid antagonist indicated for the treatment of alcohol dependence and for the blockade of the effects of exogenously administered opioids. The labeling describes that naltrexone competitively binds to opioid receptors and may block the subjective effects of opioids. Per the labeling, naltrexone may cause hepatocellular injury at higher doses; liver function should be monitored and the drug should be used with caution in patients with active liver disease. According to the Endocrine Society Clinical Practice Guideline, use of naltrexone at low doses outside labeled indications is considered off-label and requires individualized prescriber assessment and monitoring. Compounded medications are not reviewed by FDA for safety or effectiveness before dispensing. Commercially available naltrexone is separately regulated, and clinical decisions belong with the prescribing clinician.